Network Insights Methodology Whitepaper Get Access

Roche

ORG Health Care / Pharmaceuticals Momentum 6.5ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$65.2B revenue (Basel) develops pharmaceuticals and diagnostics across oncology, immunology, and infectious disease. Q1 2026 saw acceleration in personalized cancer care and AI applications; new study data signals multi-billion opportunity in breakthrough therapies.

Roche continues active M&A and investment activity in oncology, diagnostics, and AI-driven precision medicine. Recent focus on cancer care innovation and mental health integration in chronic disease management.
0.19
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
6.5
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
8
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Roche is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
AstraZeneca Pfizer PlocamiumAI Merck Europe Novartis Paris Novo Nordisk
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-28 2026-06-20 9 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
506.082
Sentiment-Momentum Divergence
0.000
Source Concentration
0.615
Signal
Roche is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #22 of 88 in Health Care — in line with sector peers. PSI stable vs yesterday (0.16).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
22 of 88
Sector Rank
+0.57
Peer Z-Score
76%
Sector Percentile
Network Analysis
8 Degree Centrality
Ego Network (top connections)
AstraZeneca (weight 4.0)Pfizer (weight 4.0)PlocamiumAI (weight 3.0)Merck (weight 3.0)Europe (weight 2.0)Novartis (weight 2.0)Paris (weight 2.0)Novo Nordisk (weight 1.0) AstraZenecaPfizerPlocamiumAIMerckEuropeNovartisParisNovo Nordisk Roche (degree 8) Roche
Centrality History
2026-05-28 2026-06-20 9 0 Degree Mentions
EntityWeight StatusFirst Seen
AstraZeneca 4 NEW
Pfizer 4 NEW
PlocamiumAI 3 NEW
Merck 3 NEW
Europe 2 NEW
Novartis 2 NEW
Paris 2 NEW
Novo Nordisk 1 NEW
Article Coverage (5)
DateLaneTitle
2026-05-27 Healthcare Marketing Roche Bets Billions on PathAI to Leapfrog Rivals in the Race For AI-Powered Pathology
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-20 ← Intelligence Network